Cytiva and Yoshindo Collaborate to Strengthen Domestic Biosimilar Manufacturing through their FlexFactory Contract in Japan

Shots: Cytiva and Yoshindo sign a FlexFactory contract to support the establishment of domestic biosimilar drug substance manufacturing in Japan. The investment is partly supported by Japan’s MHLW Yoshindo plans to supply biosimilars from its Toyama plant starting in 2028, supporting a stable and affordable biologics supply in Japan Cytiva’s FlexFactory platform uses modular bioprocessing technologies to support faster transition from facility design to GMP…

ByDipanshu DixitMarch 23, 2026

INSIGHTS+

Insights+ Key Biosimilars Events of October 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of October, Similis Bio entered into a development and…

BySenior EditorNovember 3, 2022

Cytiva and Yoshindo Collaborate to Strengthen Domestic Biosimilar Manufacturing through their FlexFactory Contract in Japan

Insights+ Key Biosimilars Events of October 2022

Contact US

FOLLOW US